A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults With Mild to Moderate Atopic Dermatitis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02376049

Enrollment

Registered

2015-03-03

Start date

2015-02-28

Completion date

2015-07-31

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

Atopic Dermatitis, Eczema, AD

Brief summary

An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis.

Detailed description

Multi-center, prospective, randomized, vehicle-controlled, investigator-blinded, stable lesion design.

Interventions

DRUGPimecrolimus cream

DRUGBetamethasone dipropionate cream

DRUGClobetasol propionate cream

DRUGGlaxal Base cream vehicle

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subject with mild to moderate AD * Four comparable TAs * TSS of at least 5 on all TAs * Difference in TSS not greater than 2 between the TAs * Sign score erythema ≥ 2 between the TAs * TAs should be at least 2 cm apart

Exclusion criteria

* Investigator's opinion * Fitzpatrick skin type \>5 * Topical (i.e. on the TAs) treatment with prohibited medications * Systemic treatment with prohibited medications * Phototherapy within prohibited timeframe * Use of emollients within prohibited timeframe

Design outcomes

Primary

Measure	Time frame	Description
Total Sign Score (TSS) change	14 days	TSS change at end of treatment in relation to baseline

Countries

Canada, Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026